Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 1:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 231 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Anticoagulation Clear all
Completed No phase listed Observational

Anticoagulation in Emergency General Surgery

NCT04216394
View directory record Official record
Conditions
Emergency General Surgery
Interventions
Emergency general surgery
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
4 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 7, 2026, 1:50 PM EDT
Completed No phase listed Observational

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study

NCT03292666
View directory record Official record
Conditions
Venous Thromboembolism, Anticoagulants and Bleeding Disorders
Interventions
Oral Anticoagulant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
39,603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Oakland, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Jun 7, 2026, 1:50 PM EDT
Recruiting Phase 3 Interventional

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
Abelacimab, Placebo
Biological · Drug
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
1,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
150
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jun 7, 2026, 1:50 PM EDT
Completed No phase listed Observational

A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics

NCT02345356
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Cardiac Valvular Insufficiency, Coagulopathies, Pulmonary Embolism
Interventions
Genotype-guided, Standard-of-Care
Genetic · Other
Lead sponsor
University of Puerto Rico
Other
Eligibility
21 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Jun 7, 2026, 1:50 PM EDT
Recruiting Not applicable Interventional

Nafamostat Efficacy in Phase 3 Registrational CRRT Study

NCT06150742
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Niyad (nafamostat mesylate), Placebo (0.9% NaCl)
Device
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Orlando, Florida • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jun 7, 2026, 1:50 PM EDT
Recruiting Phase 3 Interventional

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

NCT05836987
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
AFSW Guided DOAC, Continuous DOAC therapy
Device · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years to 85 Years
Enrollment
5,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
93
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 68 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jun 7, 2026, 1:50 PM EDT
Completed Not applicable Interventional

Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism

NCT00413504
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Fondaparinux
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2009 · Synced Jun 7, 2026, 1:50 PM EDT
Completed Phase 4 Interventional Results available

Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis

NCT00913133
View directory record Official record
Conditions
Thrombosis
Interventions
Desirudin
Drug
Lead sponsor
Canyon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
16
States / cities
Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Jun 7, 2026, 1:50 PM EDT
Completed No phase listed Observational

Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units

NCT04829552
View directory record Official record
Conditions
Covid19
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Jun 7, 2026, 1:50 PM EDT
Withdrawn Not applicable Interventional

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

NCT04684212
View directory record Official record
Conditions
Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
Interventions
LAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
Device · Drug
Lead sponsor
Brian O'Neill MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jun 7, 2026, 1:50 PM EDT
Completed Phase 4 Interventional Results available

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma

NCT02958969
View directory record Official record
Conditions
Venous Thromboembolism, Multiple Myeloma
Interventions
Apixaban
Drug
Lead sponsor
Gregory Piazza
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jun 7, 2026, 1:50 PM EDT
Withdrawn Phase 4 Interventional

Study of Left Atrial Appendage Closure in Patients With Atrial Fibrillation - III

NCT01680757
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
LARIAT Suture Delivery Device and Accessories
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2013 · Synced Jun 7, 2026, 1:50 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Shared Decision Making to Address Racial Disparities in Oral Anticoagulation in NVAF

NCT04956978
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Patient Decision Support Tool
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jun 7, 2026, 1:50 PM EDT
Withdrawn Phase 4 Interventional

Anticoagulation in AF Ablation and Effects on Neurocognitive Function

NCT02120560
View directory record Official record
Conditions
Atrial Fibrillation, Cerebrothromboembolus, Neurocognitive Function
Interventions
Atrial Fibrillation Ablation
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Jun 7, 2026, 1:50 PM EDT
Withdrawn No phase listed Observational

Arixtra PE Study- Outpatient Management of Stable Acute Pulmonary Embolism: Once Daily Subcutaneous Fondaparinux

NCT00378027
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Fondaparinux
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Jun 7, 2026, 1:50 PM EDT
Not listed Phase 2Phase 3 Interventional

Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation

NCT00691470
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction, Cardiomyopathy
Interventions
ATI-5923, Coumadin (warfarin)
Drug
Lead sponsor
ARYx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2010 · Synced Jun 7, 2026, 1:50 PM EDT
Completed Phase 4 Interventional Results available

AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)

NCT02701062
View directory record Official record
Conditions
Post-Operative Atrial Fibrillation
Interventions
AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems, Anticoagulation Therapy
Device · Drug
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
22
States / cities
San Diego, California • Stanford, California • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Jun 7, 2026, 1:50 PM EDT
Completed Phase 4 Interventional

FREEDOM COVID-19 Anticoagulation Strategy

NCT04512079
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Enoxaparin, Apixaban
Drug
Lead sponsor
Valentin Fuster
Other
Eligibility
18 Years and older
Enrollment
3,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Jun 7, 2026, 1:50 PM EDT
Recruiting No phase listed Observational

Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization

NCT03407469
View directory record Official record
Conditions
Cancer-related Venous Thromboembolism
Interventions
Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 7, 2026, 1:50 PM EDT
Completed Not applicable Interventional Results available

Improving Anticoagulation Control in VISN 1

NCT01653405
View directory record Official record
Conditions
Anticoagulants, Atrial Fibrillation, Venous Thromboembolism
Interventions
Multifaceted behavioral intervention
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
1,260,576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jun 7, 2026, 1:50 PM EDT
Recruiting Not applicable Interventional

DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

NCT05701917
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Interventions
ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
48
States / cities
Scottsdale, Arizona • Tucson, Arizona • Orange, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 7, 2026, 1:50 PM EDT
Recruiting Not applicable Interventional

Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism

NCT07399977
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis
Interventions
MSK-ACCESS, ctDNA/VTE Risk Score:
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 7, 2026, 1:50 PM EDT
Active, not recruiting Phase 4 Interventional

Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism

NCT04790370
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Anticoagulation with heparin, EkoSonicTM Endovascular System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • Newark, Delaware + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 7, 2026, 1:50 PM EDT
Completed Phase 4 Interventional Results available

Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation

NCT02608099
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Interrupted apixaban, Uninterrupted apixaban
Drug
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Huntsville, Alabama • Mission Viejo, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Jun 7, 2026, 1:50 PM EDT